TKIs inhibit the BCR/ABL oncoprotein driving the growth and persistence of CML and thus lead to the CML remission, however, it is a standard practice to administer TKIs indefinitely because of concern about relapse [107]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.